1. Home
  2. GRI vs UK Comparison

GRI vs UK Comparison

Compare GRI & UK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GRI Bio Inc.

GRI

GRI Bio Inc.

HOLD

Current Price

$0.34

Market Cap

1.9M

Sector

Health Care

ML Signal

HOLD

Logo Ucommune International Ltd

UK

Ucommune International Ltd

HOLD

Current Price

$0.81

Market Cap

1.8M

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRI
UK
Founded
2018
2015
Country
United States
China
Employees
4
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.9M
1.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GRI
UK
Price
$0.34
$0.81
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$23.00
N/A
AVG Volume (30 Days)
1.4M
20.8K
Earning Date
11-14-2025
12-29-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$20,463,860.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.31
$0.70
52 Week High
$15.64
$1.55

Technical Indicators

Market Signals
Indicator
GRI
UK
Relative Strength Index (RSI) 20.64 35.28
Support Level $0.33 $0.70
Resistance Level $2.17 $0.90
Average True Range (ATR) 0.13 0.08
MACD -0.07 -0.02
Stochastic Oscillator 1.86 37.28

Price Performance

Historical Comparison
GRI
UK

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

About UK Ucommune International Ltd

Ucommune International Ltd is a flexible office space provider and manager based in the People's Republic of China (PRC). The company offers long-term leasing, on-demand, and short-term leasing solutions to freelancers, start-up entrepreneurs, small and medium enterprises, and corporations. Company provide fully-serviced and well-furnished office spaces on a flexible basis. The members of the Ucommune community, which includes individuals and enterprises registered on the U bazaar mobile app, can avail of these services. The company has three operating segments: Workspace membership, Marketing and branding services, and Other services. Marketing and branding services generate the majority of the company's revenue.

Share on Social Networks: